The University of Texas Health Science Center, Houston
uth.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
880
Active
212
Phase 3
25
Total enrollment
281,551
Pipeline matrix
Showing 40 of 65 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Usual Care | — | — | — | — | 4 | ||
| Semaglutide | — | — | — | — | 2 | ||
| Ketorolac | — | — | — | — | — | 2 | |
| Etomidate Induction | — | — | — | — | — | 1 | |
| Propofol Induction | — | — | — | — | — | 1 | |
| PVI | — | — | — | — | — | 1 | |
| Modified Time Principle Induction (MTPI) with rocuronium | — | — | — | — | — | 1 | |
| RSI succinylcholine | — | — | — | — | — | 1 | |
| Fenfluramine treatment | — | — | — | — | — | 1 | |
| Phenylephrine | — | — | — | — | — | 1 | |
| Norepinephrine | — | — | — | — | — | 1 | |
| Irrigation with PVI | — | — | — | — | — | 1 | |
| Buprenorphine, Naloxone Drug Combination | — | — | — | — | — | 1 | |
| Suboxone | — | — | — | — | — | 1 | |
| Intervention group | — | — | — | — | — | 1 | |
| Control group | — | — | — | — | — | 1 | |
| Inhaled Nitric Oxide (iNO) use | — | — | — | — | — | 1 | |
| Maalox plus Benadryl | — | — | — | — | — | 1 | |
| Ertapenem | — | — | — | — | — | 1 | |
| Cefazolin and Metronidazole. | — | — | — | — | — | 1 | |
| Human Albumin | — | — | — | — | — | 1 | |
| Lactated Ringer's | — | — | — | — | — | 1 | |
| Treatment with Diphenhydramine | — | — | — | — | — | 1 | |
| Protonix (Pantoprazole) 40 mg q 12 hrs for 2 days | — | — | — | — | — | 1 | |
| Protonix (pantoprazole) 40 mg q 24 hrs for 2 days | — | — | — | — | — | 1 | |
| Saline delivered using an intrauterine pressure catheter | — | — | — | — | — | 1 | |
| PRIM-DJ2727 | — | — | — | — | 6 | ||
| Neoadjuvant Chemotherapy | — | — | — | — | — | 2 | |
| nicotine replacement therapy | — | — | — | — | 2 | ||
| Placebos | — | — | — | — | — | 1 | |
| usual prescribed intralipid (UL) regimen | — | — | — | — | — | 1 | |
| restricted prescribed intralipid (RL) regimen | — | — | — | — | — | 1 | |
| Immunotherapy | — | — | — | — | — | 1 | |
| Psilocybin | — | — | — | — | — | 1 | |
| Protonix (Pantoprazole) 40 mg q 12 hrs for 3 days | — | — | — | — | — | 1 | |
| Pepcid (Famotidine) 20 mg q 12 hrs for 3 days | — | — | — | — | — | 1 | |
| Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weekly | — | — | — | — | — | 1 | |
| Dose escalation to 2 mg semaglutide weekly then no semaglutide | — | — | — | — | — | 1 | |
| semaglutide 2.4mg | — | — | — | — | — | 1 | |
| Indocyanine Green near infrared fluorescence imaging | — | — | — | — | — | 1 |
25 more active programs hidden
Next readouts
- 2024-03-14
- 2025-06-01
- 2025-12
- 2026-02-27
- 2026-02-28
- 2026-05-05
- 2026-06
- 2026-06-30
- 2026-07-01
- 2026-07-31
Top conditions
- Stroke22
- Obesity20
- HIV Infections13
- Cardiovascular Diseases13
- Heart Diseases12
- Traumatic Brain Injury11
- Smoking Cessation11
- Spinal Cord Injuries10
Frequently asked questions about The University of Texas Health Science Center, Houston
- How many clinical trials does The University of Texas Health Science Center, Houston have on ClinicalTrials.gov?
- The University of Texas Health Science Center, Houston is listed as the lead sponsor on 880 clinical trials in ClinicalTrials.gov, 212 of which are currently active (recruiting, enrolling, or ongoing).
- How many of The University of Texas Health Science Center, Houston's trials are in Phase 3?
- 25 of The University of Texas Health Science Center, Houston's trials are in Phase 3, spread across 65 active drug programs.
- What therapeutic areas does The University of Texas Health Science Center, Houston focus on?
- The University of Texas Health Science Center, Houston's most-studied conditions on ClinicalTrials.gov are Stroke, Obesity, HIV Infections, Cardiovascular Diseases, Heart Diseases.
- When are The University of Texas Health Science Center, Houston's next clinical trial readouts?
- The University of Texas Health Science Center, Houston has 10 upcoming primary-completion readouts tracked here; the soonest is “Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration”, expected around 2024-03-14.